vs
STANDARD BIOTOOLS INC.（LAB）与RIVERVIEW BANCORP INC（RVSB）财务数据对比。点击上方公司名可切换其他公司
STANDARD BIOTOOLS INC.的季度营收约是RIVERVIEW BANCORP INC的1.4倍（$19.6M vs $14.0M），RIVERVIEW BANCORP INC净利率更高（9.8% vs -177.4%，领先187.2%），RIVERVIEW BANCORP INC同比增速更快（10.4% vs -11.5%），RIVERVIEW BANCORP INC自由现金流更多（$-736.0K vs $-23.1M），过去两年RIVERVIEW BANCORP INC的营收复合增速更高（24.6% vs -12.2%）
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
Riverview Bancorp Inc.是一家总部位于美国的银行控股公司，主营个人与商业银行业务，服务覆盖太平洋西北地区，提供存款、消费贷款、住房抵押贷款、商业信贷及小企业金融等产品，服务零售客户与本地企业群体。
LAB vs RVSB — 直观对比
损益表 — Q3 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $19.6M | $14.0M |
| 净利润 | $-34.7M | $1.4M |
| 毛利率 | 48.5% | — |
| 营业利润率 | -168.5% | 12.4% |
| 净利率 | -177.4% | 9.8% |
| 营收同比 | -11.5% | 10.4% |
| 净利润同比 | -28.8% | 11.8% |
| 每股收益（稀释后） | $-0.09 | $0.07 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | — | $14.0M | ||
| Q3 25 | $19.6M | $13.6M | ||
| Q2 25 | $21.8M | $13.3M | ||
| Q1 25 | $40.8M | $12.9M | ||
| Q4 24 | — | $12.7M | ||
| Q3 24 | $22.1M | $12.8M | ||
| Q2 24 | $22.5M | $12.2M | ||
| Q1 24 | $45.5M | $9.0M |
| Q4 25 | — | $1.4M | ||
| Q3 25 | $-34.7M | $1.1M | ||
| Q2 25 | $-33.5M | $1.2M | ||
| Q1 25 | $-26.0M | $1.1M | ||
| Q4 24 | — | $1.2M | ||
| Q3 24 | $-26.9M | $1.6M | ||
| Q2 24 | $-45.7M | $966.0K | ||
| Q1 24 | $-32.2M | $-3.0M |
| Q4 25 | — | — | ||
| Q3 25 | 48.5% | — | ||
| Q2 25 | 48.8% | — | ||
| Q1 25 | 48.4% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 54.9% | — | ||
| Q2 24 | 46.1% | — | ||
| Q1 24 | 53.1% | — |
| Q4 25 | — | 12.4% | ||
| Q3 25 | -168.5% | 10.2% | ||
| Q2 25 | -118.1% | 11.7% | ||
| Q1 25 | -80.8% | 11.3% | ||
| Q4 24 | — | 12.4% | ||
| Q3 24 | -120.9% | 15.5% | ||
| Q2 24 | -134.5% | 10.0% | ||
| Q1 24 | -132.2% | -47.5% |
| Q4 25 | — | 9.8% | ||
| Q3 25 | -177.4% | 8.1% | ||
| Q2 25 | -153.7% | 9.2% | ||
| Q1 25 | -63.8% | 8.9% | ||
| Q4 24 | — | 9.7% | ||
| Q3 24 | -122.0% | 12.2% | ||
| Q2 24 | -203.3% | 7.9% | ||
| Q1 24 | -70.6% | -34.7% |
| Q4 25 | — | $0.07 | ||
| Q3 25 | $-0.09 | $0.05 | ||
| Q2 25 | $-0.09 | $0.06 | ||
| Q1 25 | $-0.07 | $0.05 | ||
| Q4 24 | — | $0.06 | ||
| Q3 24 | $-0.07 | $0.07 | ||
| Q2 24 | $-0.12 | $0.05 | ||
| Q1 24 | $-0.27 | $-0.14 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $129.4M | $28.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $399.7M | $164.2M |
| 总资产 | $539.6M | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | — | $28.6M | ||
| Q3 25 | $129.4M | $32.8M | ||
| Q2 25 | $158.6M | $34.2M | ||
| Q1 25 | $150.9M | $29.4M | ||
| Q4 24 | — | $25.3M | ||
| Q3 24 | $210.6M | $31.0M | ||
| Q2 24 | $269.8M | $27.8M | ||
| Q1 24 | $287.1M | $23.6M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $55.2M | — | ||
| Q2 24 | $55.1M | — | ||
| Q1 24 | $55.0M | — |
| Q4 25 | — | $164.2M | ||
| Q3 25 | $399.7M | $163.5M | ||
| Q2 25 | $424.5M | $162.0M | ||
| Q1 25 | $454.6M | $160.0M | ||
| Q4 24 | — | $158.3M | ||
| Q3 24 | $489.3M | $160.8M | ||
| Q2 24 | $510.3M | $155.9M | ||
| Q1 24 | $577.3M | $155.6M |
| Q4 25 | — | $1.5B | ||
| Q3 25 | $539.6M | $1.5B | ||
| Q2 25 | $557.0M | $1.5B | ||
| Q1 25 | $579.6M | $1.5B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | $681.5M | $1.5B | ||
| Q2 24 | $708.7M | $1.5B | ||
| Q1 24 | $777.7M | $1.5B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.11× | — | ||
| Q2 24 | 0.11× | — | ||
| Q1 24 | 0.10× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-22.2M | $-506.0K |
| 自由现金流经营现金流 - 资本支出 | $-23.1M | $-736.0K |
| 自由现金流率自由现金流/营收 | -118.1% | -5.2% |
| 资本支出强度资本支出/营收 | 4.5% | 1.6% |
| 现金转化率经营现金流/净利润 | — | -0.37× |
| 过去12个月自由现金流最近4个季度 | $-111.1M | $20.4M |
8季度趋势，按日历期对齐
| Q4 25 | — | $-506.0K | ||
| Q3 25 | $-22.2M | $16.8M | ||
| Q2 25 | $-20.7M | $-697.0K | ||
| Q1 25 | $-30.3M | $8.3M | ||
| Q4 24 | — | $2.2M | ||
| Q3 24 | $-27.9M | $764.0K | ||
| Q2 24 | $-39.0M | $5.4M | ||
| Q1 24 | $-62.5M | $12.8M |
| Q4 25 | — | $-736.0K | ||
| Q3 25 | $-23.1M | $16.4M | ||
| Q2 25 | $-22.6M | $-773.0K | ||
| Q1 25 | $-35.3M | $5.6M | ||
| Q4 24 | — | $1.9M | ||
| Q3 24 | $-30.1M | $-1.4M | ||
| Q2 24 | $-41.0M | $5.3M | ||
| Q1 24 | $-63.3M | $7.1M |
| Q4 25 | — | -5.2% | ||
| Q3 25 | -118.1% | 120.1% | ||
| Q2 25 | -103.6% | -5.8% | ||
| Q1 25 | -86.6% | 43.1% | ||
| Q4 24 | — | 15.0% | ||
| Q3 24 | -136.4% | -11.3% | ||
| Q2 24 | -182.2% | 43.7% | ||
| Q1 24 | -138.9% | 79.0% |
| Q4 25 | — | 1.6% | ||
| Q3 25 | 4.5% | 2.9% | ||
| Q2 25 | 8.7% | 0.6% | ||
| Q1 25 | 12.4% | 21.0% | ||
| Q4 24 | — | 2.4% | ||
| Q3 24 | 10.2% | 17.3% | ||
| Q2 24 | 8.6% | 0.9% | ||
| Q1 24 | 1.7% | 62.0% |
| Q4 25 | — | -0.37× | ||
| Q3 25 | — | 15.25× | ||
| Q2 25 | — | -0.57× | ||
| Q1 25 | — | 7.20× | ||
| Q4 24 | — | 1.79× | ||
| Q3 24 | — | 0.49× | ||
| Q2 24 | — | 5.63× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LAB
| Consumables | $8.7M | 45% |
| Services And Other Revenue | $5.8M | 29% |
| Instruments | $5.1M | 26% |
RVSB
暂无分部数据
